Amgen Stock Price Lingers Below Fair Value Amid Data Breach Concerns

Amgen's stock price has delivered a strong 116.3% return over the past five years, but current checks indicate a mixed picture.

The company's planned Science and Innovation Center in Hyderabad is expected to support future research productivity and cash flow, but recent data breaches and questions surrounding Tavneos create uncertainty that may impact investor pricing of those future cash flows.

The Discounted Cash Flow (DCF) model estimates Amgen's intrinsic value at about $668 per share, compared to the current market price around $417.84, implying a 37.4% undervaluation.

The P/E ratio view suggests Amgen is priced roughly fairly valued relative to peers, but investors weigh potential operational and regulatory risks against cash generation.